12:00 AM
Aug 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

23andMe Personal Genome Service regulatory update

23andMe said it submitted 510(k) documentation to FDA for 7 undisclosed tests, which are among those offered by its Personal Genome Service. The tests will be reviewed under a de novo pathway, an alternative path to...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >